British Journal of Pharmacology · 2022 · 16 citations · 35 references
Life SciencesImmunologyPharmacologyImmunopathologyImmunotherapyInflammationInflammatory SignalingLeukocyte AdhesionLeukocyte TraffickingLung TargetingNanocarriers For TherapeuticsSystemic SclerosisCell InfiltrationEverolimus InteractionsEverolimus TreatmentLung FibrosisNanoparticle-based ImmunotherapyP-selectin ExpressionPulmonary LiposomesTargeted Pulmonary Nanomedicine
BACKGROUND AND PURPOSE: Interstitial lung disease (ILD) is the main cause of mortality in systemic sclerosis (SSc), and current therapies available are of low efficacy or high toxicity. Thus, the identification of innovative less toxic and high efficacy therapeutic approaches to ILD treatment is an urgent need. The interaction of P-selectin glycoprotein ligand-1 (PSGL-1) with P-selectin initiates leukocyte extravasation and deletion of the corresponding gene (Selplg) induces a SSc-like syndrome with high incidence of ILD in aged mice. EXPERIMENTAL APPROACH: ) mice were used to assess the therapeutic effects of nanotherapy with everolimus, included in liposomes decorated with high MW hyaluronic acid (LipHA+Ev) and administered intratracheally to specifically target CD44-expressing lung cells. KEY RESULTS: PSGL-1 KO mice had increased numbers of CD45+ and CD45- cells, including alveolar and interstitial macrophages, eosinophils, granulocytes and NK cells, and myofibroblasts in bronchoalveolar lavage (BAL). CD45+ and CD45- cells expressing pro-inflammatory and pro-fibrotic cytokines were also increased. Lungs from PSGL-1 KO mice showed increased immune cell infiltration and apoptosis and exacerbated interstitial and peribronchial fibrosis. Targeted nanotherapy with LipHA+Ev decreased the myofibroblasts in BAL, cells producing proinflammatory and profibrotic cytokines, and the degree of lung inflammation at histology. LipHA+Ev treatment also decreased the severity of peribronchial and interstitial lung fibrosis, from moderate to mild levels. CONCLUSIONS AND IMPLICATIONS: In PSGL-1 KO mice, targeted nanotherapy with LipHA+Ev was an effective treatment for SSc-ILD, reducing the number of inflammatory and fibrotic cells in BAL and reducing inflammation and fibrosis in lungs.
35
The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research
Nathalie Percie du Sert, Viki Hurst, Amrita Ahluwalia et al. · PLoS Biology · 2020 · 5.6K citations · Full text
Keith C. Meyer, Ganesh Raghu, Robert P. Baughman et al. · American Journal of Respiratory and Critical Care Medicine · 2012 · 1.1K citations
Ulrich A. Walker, Alan Tyndall, L. Czirják et al. · Annals of the Rheumatic Diseases · 2007 · 922 citations · Full text
Hyaluronic Acid in Inflammation and Tissue Regeneration.
Małgorzata Litwiniuk, Alicja Krejner, Marcus S Speyrer et al. · PubMed · 2016 · 528 citations